Clinical trials: Diabetes Type II
Diabetes Mellitus, Type 2, Cardiovascular Diseases
A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease
COORDINATE-Diabetes is a cluster-randomized clinical trial to test the effectiveness of an innovative, clinic-level educational intervention to improve the management of patients with type 2 diabetes mellitus and cardiovascular…
- Trial name
- COORDINATE (NCT03936660)
- Testing
- Intense Education Intervention
- Where
- 44 sites in United States
- Volunteers
- 1,049 people
- Sponsor
- Duke University
Diabetes Mellitus, Type 2
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
- Trial name
- NCT01289990
- Testing
- BI 10773, Sitagliptin 100mg
- Where
- 243 sites in United States, Belgium and 17 more
- Volunteers
- 2,705 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to once-daily insulin glargine in participants with type 2 diabetes mellitus who have inadequate glycemic control with 1 or 2 oral…
- Trial name
- AWARD-CHN2 (NCT01648582)
- Testing
- Dulaglutide, Insulin glargine, Metformin
- Where
- 30 sites in China, Mexico and 2 more
- Volunteers
- 774 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of LY3025876 in Participants With Diabetes
The main purpose of this study is to assess the safety and tolerability of LY3025876 given alone (Part A) and in combination with liraglutide (Part B) in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01870297
- Testing
- LY3025876, Liraglutide
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of combination therapy with dulaglutide and insulin in Japanese participants with type 2 diabetes.
- Trial name
- NCT02750410
- Testing
- Dulaglutide
- Where
- 25 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Eli Lilly and Company
Pre-diabetes, Older Adults
Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.
The goal of this study is to evaluate the hypothesis that the addition of liraglutide, a long-acting glucagon-like peptide 1 (GLP-1) analogue, to a calorie-restricted diet will lead to greater weight loss than will a…
- Trial name
- NCT01784965
- Testing
- liraglutide
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Stanford University
Type 2 Diabetes, Obesity
EndoBarrier in Obese Subjects With Type 2 Diabetes Mellitus
The aim of the study is to explore short and longer-term effects of the Endobarrier™ implantation on insulin resistance and beta-cell function assessed by repeated Botnia clamps.
- Trial name
- NCT02769728
- Testing
- EndoBarrier
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Graz
Diabetes Mellitus, Type 2
Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes
This is a Phase 4, prospective, open label, randomized, parallel controlled multicenter trial in which metformin extended release (XR) will be compared with metformin immediate release (IR) for the gastrointestinal tolerability…
- Trial name
- CONSENT (NCT02252965)
- Testing
- Metformin IR, Metformin XR
- Where
- Germany
- Volunteers
- 532 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Diabetes Mellitus
Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin
This is a study to evaluate the safety, tolerability, and activity of OAP-189 in subjects with type 2 diabetes who are taking metformin for their diabetes.
- Trial name
- 3283K1-1008-US (NCT00970593)
- Testing
- OAP-189
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
This multicenter, randomized, double-blind, placebo controlled, parallel group study is being conducted to provide data on efficacy, safety, tolerability and pharmacokinetics (PK) of multiple dose levels of PF-06882961 in adults…
- Trial name
- NCT03985293
- Testing
- PF-06882961
- Where
- 83 sites in United States, Bulgaria and 6 more
- Volunteers
- 412 people
- Sponsor
- Pfizer
Type 2 Diabetes
START-J: SiTAgliptin in eldeRly Trial in Japan
The purpose of this study is to compare the efficacy and the safety of sitagliptin and glimepiride in drug naïve elderly patients with Type 2 diabetes as evaluated by HbA1c change from baseline at 52 W as efficacy and incidence…
- Trial name
- START-J (NCT01183104)
- Testing
- Sitagliptin, Glimepiride
- Where
- Japan
- Volunteers
- 305 people
- Sponsor
- Japan Association for Diabetes Education and Care
Type 2 Diabetes Mellitus
Study of AC-201 in Patients With Type 2 Diabetes Mellitus
This is a 24-week randomized placebo-controlled study to investigate the effect of an oral IL-1beta inhibitor AC-201 in patients with type 2 diabetes mellitus already treated on different background diabetes therapies.
- Trial name
- NCT01276106
- Testing
- AC-201, 25mg, AC-201, 50mg, AC-201, 75mg
- Where
- 21 sites in United States, Taiwan
- Volunteers
- 259 people
- Sponsor
- TWi Biotechnology, Inc.
Obesity, Overweight
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program.
- Trial name
- SURMOUNT-3 (NCT04657016)
- Testing
- Tirzepatide
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 579 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Alogliptin Tablets Specified Drug-use Survey "Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"
The purpose of this survey is to evaluate the safety and efficacy of long-term use of alogliptin tablets (Nesina Tablets) in type 2 diabetic patients who have had an inadequate response to hypoglycemic agents (e.g., insulin…
- Trial name
- NCT02221284
- Testing
- Alogliptin
- Where
- 2 sites in Japan
- Volunteers
- 964 people
- Sponsor
- Takeda
Type 2 Diabetes
Impact of Mulberry Leaf on Type 2 Diabetes
The purpose of this study is to evaluate whether mulberry leaf extract will help control blood sugar in patients with type 2 diabetes. We also want to look at the safety of mulberry leaf extract in these patients.
- Trial name
- Mul-DM (NCT00795704)
- Testing
- Mulberry Leaf Extract
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Mississippi Medical Center
Diabetes Mellitus, Type 2
Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)
The purpose of this clinical study is to determine the safety and efficacy of an investigational drug in patients with Type 2 diabetes mellitus.
- Trial name
- NCT00106704
- Testing
- Comparator: Sitagliptin, Comparator: Pioglitazone
- Volunteers
- 441 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Diabetes and Gastric By- Pass
The purpose of this study is to evaluate the mechanisms leading to rapid postoperative improvement in diabetes following Gastric By-Pass surgery for obesity.We will evaluate and compare the changes in glucose level, beta-cell…
- Trial name
- NCT01153516
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Type 2
Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)
Background: Type II diabetes is a disease that affects more than 246 million people worldwide. Most importantly, one of the complications of type II diabetes is kidney damage and this has lead to many patients seeking…
- Trial name
- NCT01359904
- Testing
- High Dialysate bath
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
This study will help determine the effect of Glucagon Like Peptide-1 (GLP-1)receptor agonists on bone strength in postmenopausal women with type 2 diabetes mellitus (T2DM)
- Trial name
- NCT04964388
- Testing
- GLP-1 receptor agonist
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Mississippi Medical Center
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes
This study will investigate how the body processes nasal glucagon (NG) and the effect of nasal glucagon on the body. The study is expected to last about 50 days for each participant.
- Trial name
- NCT02806973
- Testing
- Nasal Glucagon
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.